Fuad El-Hibri Blog

Lebanese CEO Sees Opportunity in Current Crisis

October 15, 2009
Leave a Comment

Daily Star

July 10, 2009

http://www.dailystar.com.lb/article.asp?edition_id=1&categ_id=3&article_id=104008

Chairman and CEO Fouad El Hibri insists that good business opportunities often arise in time of crisis, which he considers the best time for entrepreneurs to invest in new projects. “When the market is down, I believe that good opportunities arise and investors have better chances to find assets that are undervalued and able to provide wonderful returns in the future,” Hibri told The Daily Star.

“I see within any turmoil great opportunities,” he said.

Hibri, an American entrepreneur with Lebanese heritage, is the winner of Ernst & Young Entrepreneur of the Year 2009 Award in the Technology category in greater Washington. With great persistence and commitment,Hibri was able to successfully grow a pharmaceutical biotech facility that is worth hundreds of millions of dollars and was previously owned and run by the state of Michigan.

Posted in Business Contracts, BusinessWeek, DailyPress, El-Hibri Foundation, El-Hibri Fuad
Tags: , , , , ,

Fuad El-Hibri on DailyPress

June 14, 2009
1 Comment

Fuad El-Hibri on DailyPress

<b>Key people related to BioPort:</b> Fuad El-Hibri and fellow investors bought BioPort.

Buy

//

Key people related to BioPort: Fuad El-Hibri and fellow investors bought BioPort.
Reblog this post [with Zemanta]
Posted in DailyPress, El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri
Tags: , , , , , , ,

About author

Mr. Fuad El-Hibri is the Chairman and Chief Executive Officer of Emergent BioSolutions Inc. (Emergent), a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing vaccines and therapeutics to prevent and treat life-threatening diseases. The company’s current marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only FDA-licensed vaccine for pre-exposure prophylaxis of anthrax disease. The company is also investing heavily in the development of a broad pipeline of products that address specific global unmet medical needs, including Typhoid, Tuberculosis, Hepatitis B and Chlamydia. Mr. El-Hibri has extensive experience in the biopharmaceutical industry beginning with Porton Products, Ltd. (Porton), a mid-sized biotechnology company in the United Kingdom. Subsequent to the successful marketing and distribution of Porton’s biodefense vaccines to foreign governments in the early 1990’s, Mr. El-Hibri organized a management buyout of Porton in 1994, forming Speywood Holdings, Ltd. He was appointed to the Board of Directors of Speywood Holdings, Ltd. and acted as an advisor to the senior management team in the operations of the company until 1996. Starting in the 1990’s, Mr. El-hibri formed and then sold three mobile telecommunications companies, Mobile TeleSystems, serving the greater Moscow region, as well as Digitel and Digicel, serving markets in South and Central America. Mr. El-Hibri began his career with Citigroup in commercial banking and subsequently in mergers & acquisitions. Following his tenure at Citigroup, Mr. El-Hibri joined Booz Allen & Hamilton as a management consultant in South East Asia, where he led several large client engagements.

Search

Navigation

Categories:

Links:

Archives:

Feeds